EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression

Juan Miguel Riestra, Yaxel Levin‐Carrion, Roshan Sutar, Jessica Mitchell, Pranav Jambulingam, Santiago J. Ballaz, Mujeeb U. Shad, Shafiqur Rahman, Stefano Barlati, Maju Mathew Koola

Human Psychopharmacology: Clinical and Experimental · 2026-05 · 41 (3)

DOI: 10.1002/hup.70039 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Treatment‐resistant depression (TRD) remains a formidable challenge in psychiatry, with nearly one‐third of patients with major depressive disorder (MDD) failing to respond adequately to first‐line pharmacological treatments. Pathophysiology in MDD has highlighted the N‐methyl‐D‐aspartate (NMDA) glutamatergic system as a promising therapeutic target. In 2022, the US Food and Drug Administration (FDA) approved the bupropion and dextromethorphan (DXM) combination (BDC), the first oral combination that affects both the NMDA receptor and norepinephrine‐dopamine systems. DXM is an uncompetitive NMDA receptor antagonist, and in combination with bupropion, it has been shown to be a rapidly acting oral medication with clinically significant improvement in the first week of treatment. BDC, however, has many inherent limitations such as contraindications in those with eating disorders and a history of seizures. Anxiety is a common comorbidity in MDD, and bupropion has been shown to lack efficacy in treating anxiety. In addition, BDC did not improve cognition. Memantine can treat depression and cognitive impairments concurrently. Fixed‐dose combination pills can be less flexible than prescribing each drug separately, as BDC is limited to a 105 mg (bupropion)‐45 mg (DXM) combination. The projected 1‐month cost of possible combinations of memantine ($5.00) with a selective serotonin reuptake inhibitor (SSRI, $4.00), serotonin‐norepinephrine reuptake inhibitor (SNRI, $15.00), and bupropion ($18.00) are cheaper than BDC ($1119.00). Instead of BDC, we propose various alternatives such as a bupropion‐memantine combination or SSRI/SNRI and memantine for MDD/TRD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →